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ABSTRACT. Mobile electrocardiograms (ECGs) (mECGs) using smartphone applications are 
an emerging technology. In the coronavirus disease 2019 (COVID-19) era, minimizing patient 
contact has gained increasing importance. Additionally, increased QT/corrected QT (QTc) mon-
itoring has concurrently been required. The KardiaMobile 6L ECG device, cleared by the United 
States Food and Drug Administration (FDA) for recording ECGs, along with the KardiaStation 
tablet application is a platform (AliveCor, Mountain View, CA, USA) that addresses these two 
issues. A team of residents, fellows, hospitalists, and cardiologists identified inpatients in need 
of QT/QTc interval monitoring to pilot the adoption of a system composed of a KardiaMobile 6L 
ECG device with the accompanying KardiaStation tablet application. Concurrent standard ECGs 
provided validation. Adoption and performance issues were recorded. Four patients agreed to par-
ticipate in QT/QTc interval monitoring, three of whom were positive for severe acute respiratory 
syndrome coronavirus 2 viral infection. After basic instructions were given to the patients and 
their clinical nurses, all patients recorded mECGs successfully. Patients were able to record their 
own mECG tracings at least once without any assistance. The 12-lead ECGs and mECGs each 
showed the correct rhythm, and the measured QTc intervals on each modality were consistently 
acceptable (< 500 ms). Contactless ECGs were successfully uploaded to KardiaStation for QT/
QTc interval measurement and archiving. In this study, we showed that an FDA-cleared product, 
KardiaMobile 6L, has the ability to provide high-quality contactless ECGs for reliable QT/QTc 
interval measurements. Hospitalized patients were able to perform recordings when requested after 
receiving simple instructions at the time of first use. This technology has applications during the 
COVID-19 pandemic and beyond.
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Introduction
Patients with prolonged QT/corrected QT (QTc) inter-
vals are at a greater risk for torsades de pointes and 
subsequent ventricular fibrillation and sudden cardiac 
death.1 A prolonged QTc interval is a known side effect 
of several hundred medications, including hydroxychlo-
roquine and azithromycin, two drugs that were used to 
treat patients with coronavirus disease 2019 (COVID-19) 
in abundance early on in the clinical experience with 
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this viral condition.1–3 Patients with known and sus-
pected arrhythmias are common in outpatient practice.4 
Advances in mobile technology are widely available 
and extend the scope of remote monitoring beyond that 
of conventional medically prescribed products. A com-
mercially available mobile electrocardiogram (mECG) 
device, KardiaMobile (AliveCor, Mountain View, CA, 
USA), is relatively inexpensive and works with a smart-
phone or tablet application; using sensors for fingers 
from the right and left hands, it provides a 30-second 
or longer tracing corresponding to lead I of a standard 
12-lead ECG. Compared with simple pulse rate monitors, 
the ability to record ECG information is more useful for 
arrhythmia diagnosis.5 Beyond the ability of patients to 
record their own mECGs, AliveCor offers a subscription 
service, KardiaPro, which logs the mECG recordings for 
collection and review. Since 2017, our institution, Thomas 
Jefferson University Hospital, has registered outpatients 
to this encrypted, practice-managed service.
The KardiaMobile mECG device has been used experi-
mentally in a variety of ambulatory settings to detect 
arrhythmias and conduction system abnormalities such 
as atrial fibrillation, to monitor QT/QTc intervals during 
antiarrhythmic drug initiation, and to diagnose myocar-
dial infarction.6–10 These proof-of-concept studies largely 
have depended on single-lead measurements made man-
ually, which provide less information than what is avail-
able with a multilead analysis. Previously, we developed 
a method to record alternate ECG leads (aside from lead 
I) using the mECG device.11 We observed that patients 
were able to use the technology without difficulty. In May 
2019, the United States Food and Drug Administration 
(FDA) granted clearance to the KardiaMobile 6L device, 
the first-ever, personal six-lead ECG device; KardiaMo-
bile 6L records six of the 12 leads usually obtained from 
a standard ECG (ie, the limb leads are recorded but not 
the precordial leads). A six-lead tracing is recorded by 
placing a person’s right and left fingers or thumbs on the 
corresponding electrodes on the top surface of the device 
while simultaneously placing the electrode on the bottom 
surface of the device against the skin on the left lower 
extremity.
On March 23, 2020, the FDA issued an enforcement 
policy to help expand the availability and capability of 
noninvasive remote monitoring devices, such as Kardia-
Mobile 6L, to facilitate patient monitoring while reducing 
patient and health care provider contact and exposure to 
patients positive for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection for the duration 
of the COVID-19 public health emergency. This policy 
enabled the use of the KardiaMobile 6L device for QT/
QTc interval monitoring to improve patient safety while 
administering potential QT/QTc interval–prolonging 
medications.5
Given the limited experience with using mECGs in 
the inpatient setting and the use of potential QT/QTc 
interval–prolonging medications (hydroxychloroquine 
and azithromycin) in COVID-19 patients, we sought to 
describe our experience with this technology. The purpose 
of this case series was to assess the feasibility of recording 
using the commercially available mECG device, Kardia-
Mobile 6L, along with a tablet application (KardiaStation; 
AliveCor) in inpatients needing intermittent ECG moni-
toring. We also sought to document the ease of use of con-
tactless ECG recordings and to compare contactless ECG 
recordings from the KardiaMobile 6L with standard ECG 
recordings, which require medical personnel to come into 
close proximity with  COVID-19–positive patients. Our 
aim was to derive clinical practice lessons for the use of 
Kardia Mobile 6L beyond the COVID-19 pandemic, as we 
believe that heightened infectious disease protocols mini-
mizing health care provider and patient exposure will be 
the “new norm” in inpatient management.
Methods
Patient population
Eligible participants included male and female COVID-
19–positive patients or patients requiring ECG monitor-
ing who were at least 18 years of age. All patients were 
diagnosed using nasal swabs. Study participants were 
not on telemetry but required intermittent ECG monitor-
ing and had no prior experience using an mECG device. 
Among suspected or confirmed COVID-19–positive 
patients, respiratory isolation precautions were used. 
Hydroxychloroquine and azithromycin were adminis-
tered due to the experimental use of these treatments for 
the management of COVID-19–related clinical sequelae 
at the time of the study. We included patients with QTc 
interval values of greater than 500 ms, as we deemed them 
to be at high risk for torsades de pointes. We excluded 
patients unwilling or unable to use the KardiaMobile 6L 
device and those who needed continuous telemetry.
Endpoints
The primary goals of this study were to assess the fea-
sibility of obtaining recordings using the commercially 
available KardiaMobile 6L mECG device together with 
a tablet application (KardiaStation) among inpatients 
needing intermittent ECG monitoring and to qualita-
tively compare the results with standard 12-lead ECG 
recordings. The secondary purpose was to determine 
whether patients could perform their own recordings 
with the device when the health care provider is outside 
the room (ie, a contactless recording). We hypothesized 
that KardiaMobile 6L would be able to yield an accurate 
ECG recording in a contactless manner.
Study procedures
The manufacturer provided several KardiaMobile 6L 
devices, a dedicated iPad tablet (Apple, Inc., Cupertino, 
CA, USA), and a demonstration version of the 
KardiaStation application (Figure 1). On the same tab-
let, we created a shortcut to our institutional KardiaPro 
account. Additionally, we connected to the hospital 
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WiFi and had access to the institutional electronic health 
records.
The multidisciplinary care team, consisting of cardiolo-
gists, hospitalists, and nurses, met initially by video con-
ference to discuss the mECG product and software. Once 
a hospitalist identified a potential patient, the team mem-
bers communicated electronically about eligibility for 
inclusion. A resident or fellow (D. R. F., E. S. F., or D. J. F.) 
spoke either to the patient’s nurse or directly to the patient 
to explain the system; consent for patient inclusion in this 
research was attained during the first encounter between 
the patient and the cardiologist or cardiology fellow. One 
of the team members showed the nurse how to com-
plete a recording by using a demonstration device and 
the iPad. The nurse then had the opportunity to ask any 
clarifying questions and to ensure she or he  understood 
how to use the device. To minimize direct contact, these 
conversations were generally held via telephone with the 
health care provider outside the room. The next time that 
the nurse went into the room for clinical care, she or he 
educated the patient on how to use the device. Patients 
were also provided with written instructions in English. 
Within their rooms, patients were brought to within 10 
feet of the door (Bluetooth range). One of the cardiolo-
gists then stood at the closed door while the patient per-
formed the recordings (Figure 1). Patients completed two 
recordings using the KardiaMobile 6L device with the 
health care provider outside the room. After a successful 
recording, the cardiologist let the patient know that the 
recording had been completed. A nurse was sometimes in 
the room during the initial recording, but to fulfill other 
caregiving responsibilities rather than assist with the 
recording.
Next, WiFi connectivity was verified and QT/QTc 
interval analysis was requested through the KardiaPro 
account. Once requested, the QT/QTc interval analysis 
was performed by BioTelemetry, Inc. (Malvern, PA, USA), 
an independent third-party QTc measuring service that 
has performed nearly 4,000 QT interval measurements 
to date. Within one hour, one of the cardiologists then 
logged on to the KardiaPro website to review the mECG, 
the automatic interpretation, and the QT/QTc interval 
measurements reported by the third-party source. At the 
time of discharge, the three COVID-19–positive patients 
kept the provided KardiaMobile 6L devices and were told 
about the ability to subscribe to the Kardia system as out-
patients. At the cardiologist’s or cardiology fellow’s dis-
cretion, patients also received nonmobile ECGs for QT/
QTc interval monitoring within one day of the mobile 
recordings.
Statistical methods
This was a descriptive study without statistical analy-
sis. This study was approved by the Thomas Jefferson 
University Hospital Institutional Review Board.
Results
Of the six consecutive patients approached for the study, 
four agreed to participate. The two who did not partici-
pate stated that they were not interested. Demographics, 
ECG results, and mECG results are recorded in Table 1. 
Representative ECG and mECG recordings are shown in 
Figure 2.
Patient 1
Patient 1 was a 45-year-old man with a medical history 
of renal cancer (who underwent left nephrectomy and a 
renal transplant), hypertension, morbid obesity, and sleep 
apnea. The patient presented with progressive fatigue and 
intermittent chills for five days and loose stools for one day. 
On the advice of his nephrologist, the patient presented to 
A
B
Figure 1: The KardiaMobile 6L device. A: By placing two 
thumbs on the device and holding it against the knee, a 
six-lead ECG recording can be taken. B: A clinician uses the 
KardiaStation app on an iPad tablet outside of the patient’s 
room while the patient takes measurements inside their 
room. Images courtesy of AliveCor.
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the emergency department for evaluation. An evaluation 
confirmed SARS-CoV-2 infection, and he was started on 
a five-day course of  hydroxychloroquine. He was able to 
complete two recordings using the KardiaMobile 6L with 
the health care provider outside the room. At discharge, 
his inflammatory markers remained elevated but stable.
Patient 2
Patient 2 was a 48-year-old Spanish-speaking man with no 
significant medical history who presented with a cough 
and worsening dyspnea; an evaluation subsequently con-
firmed SARS-CoV-2 infection. During his hospitalization, 
he never required supplemental oxygen and was able to 
ambulate without desaturation while breathing room air. 
He was given a several-day course of hydroxychloroquine, 
which was initiated upon admission. He remained on 
room air with stable inflammatory  markers and was dis-
charged with instructions for COVID-19 precautions. His 
nurse provided instructions to him in Spanish, and he was 
able to complete two recordings using the KardiaMobile 
6L with the health care provider outside the room.
As standard of care, this patient also received nonmobile 
ECGs for QT/QTc interval monitoring within one day 
of the mobile recordings. A comparison of the two ECG 
readings revealed similar automatic rhythm interpreta-
tions and QT/QTc interval calculations.
Patient 3
Patient 3 was a 67-year-old man with advanced systolic 
heart failure and persistent atrial fibrillation who pre-
sented with acute decompensated heart failure. Because of 
the lack of response to therapies in the intensive care unit, 
he was transferred to the telemetry ward for consideration 
of palliative care options. After an unanticipated clinical 
improvement with diuretic therapy and following further 
discussion with the patient, he agreed to slowly intensify 
medical therapy again. However, he requested minimal 
invasiveness and testing. Given this request, we proceeded 
with implementing contactless ECG monitoring. Although 
he did not have COVID-19, his diagnosis of significant car-
diomyopathy and anticipated electrolyte shifts clinically 
justified the use of intermittent ECG monitoring. He was 
able to complete two recordings using the KardiaMobile 6L 
device with the health care provider outside of the room.
Patient 4
Patient 4 was a 96-year-old woman with atrial fibrillation 
treated with anticoagulation therapy, mild aortic steno-
sis, dyslipidemia, hypertension, chronic kidney disease, 
and anemia who presented with subjective palpitations 
and was found to have atrial fibrillation with a rapid 
response. One week prior to the current admission, she 
was hospitalized for near-syncope and was found to be 
positive for COVID-19. She was treated with hydroxy-
chloroquine for five days and also with ceftriaxone and 
azithromycin for superimposed pneumonia. Due to var-
iable heart rates, ECG monitoring was required. Despite 
our initial concerns about this patient’s mobility, “techno-
logy literacy,” and frailty, she was able to complete two 
recordings using the KardiaMobile 6L device with the 
health care provider outside the room.
This patient also received a nonmobile ECG within one 
day for validation. A comparison of the two ECG readings 
















ECG 1 Sinus rhythm (83 bpm) 372/437 N/A
ECG 2 Sinus rhythm (88 bpm) 372/450 N/A
Kardia 1 Tachycardia (102 bpm) 360/469* Yes




ECG 1 Sinus rhythm (97 bpm) 380/483 N/A
ECG 2 Sinus rhythm (89 bpm) 384/468 N/A
Kardia 1 Normal (99 bpm) 327/419 Yes




ECG 1 AF (97 bpm) 348/442 N/A
ECG 2 AF (103 bpm) 376/492 N/A
Kardia 1 Possible AF (98 bpm) 373/462 Yes




ECG 1 AF (103 bpm) 353/462 N/A
ECG 2 AF (120 bpm) 339/479 N/A
Kardia 1 N/A N/A Yes
Kardia 2 Possible AF (83 bpm) 363/430 Yes
AF: atrial fibrillation; COVID-19: coronavirus disease 2019; ECG: electrocardiogram; 
mECG: mobile electrocardiogram; N/A: not available; QTc: corrected QT.
*Manual measurement.
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revealed similar automatic rhythm interpretations and 
QTc interval calculations.
Key lessons
Key lessons from our case series are noted in Tables 2 
and 3. These include the need for both patient and pro-
vider education about the logistics and utility of this 
ECG method as well as the need for resources beyond 
the KardiaMobile 6L device itself (ie, a reliable wireless 
Internet connection and a tablet computer).
Discussion
mECG devices have previously been used in ambulatory 
detection of atrial fibrillation with high sensitivity and 
Figure 2: Representative ECGs and mECGs from two patients. A: ECG from patient 2. B: Six-lead mECG from patient 2. Note that 
the automatic rhythm interpretations are correct and the QTc intervals are less than 500 ms. Note that 40-ms vertical gridlines 
have been added to aid in the ability to measure the QT interval manually.
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specificity. In this case series, we found that patients were 
able to use the mECG product for QT/QTc interval mon-
itoring in an inpatient setting and that accurate record-
ings were obtainable despite the health care provider not 
being in contact with the patient. Although not assessed 
formally, repeat measurements anecdotally required less 
instruction than the initial measurement and could be 
completed within minutes. Furthermore, this techno-
logy delivered consistent, accurate results among special 
patient populations (eg, non-English speakers, patients 
with advanced heart failure, and elderly and frail 
individuals). Furthermore, we observed that this method 
of ECG monitoring can be reliably deployed among hos-
pitalized COVID-19–positive patients. Our case series 
provides evidence that the use of KardiaMobile 6L can 
likely be extended beyond inpatient COVID-19–related 
rhythm monitoring and into the outpatient realm.
KardiaMobile 6L uses a unique technology that can record 
high-quality ECGs of all six limb leads. The technology 
allows the recordings to be transferred from a mobile 
device via KardiaStation to an independent diagnostic 
Figure 2: Continued. C: ECG from patient 4. D: Six-lead mECG from patient 4. Note that the automatic rhythm interpretations 
are correct and the QTc intervals are less than 500 ms. Note that 40-ms vertical gridlines have been added to the mECG tracings 
to aid in the ability to measure the QT interval manually.
D. R. Frisch, E. S. Frankel, D. J. Farzad, et al.
4438 The Journal of Innovations in Cardiac Rhythm Management, March 2021
testing facility that can quantify QT/QTc intervals rap-
idly and then return the information to frontline health 
care providers. The recordings from the KardiaStation 
application automatically synchronize to the KardiaPro 
physician portal, where clinicians can review the col-
lected data. Unlike most ambulatory ECGs, by virtue 
of including all six of the limb leads, KardiaMobile 6L 
includes lead II data, which frequently offer a more accu-
rate view of the QT/QTc interval than data for lead I.12
During times of crisis such as the COVID-19 pandemic, 
when QT/QTc interval–prolonging medications are 
used, there is high utility in reliably measuring the QT/
QTc interval accurately for both inpatient and outpatient 
use. KardiaMobile 6L offers expedited recordings and, 
within minutes, can provide information to health care 
providers. The device is small and recordings can be per-
formed by patients within their rooms. This minimizes 
close contact with frontline health care providers, poten-
tially reducing the spread of COVID-19 or other infec-
tious diseases to essential personnel and other patients. 
Furthermore, because of its availability and ease of use, 
the KardiaMobile 6L device addresses the potential short-
age of remote ECG machines in a cost-effective manner 
given the infection-control protocols.13
The use of wearable and patient-owned medical prod-
ucts is likely to increase in the era of heightened infec-
tious disease protocols during and following the COVID-
19 pandemic. Minimizing patient-to-provider and 
patient-to-patient contact is a priority in every hospital 
process. Essential processes that subject health care pro-
viders to high patient exposure, ranging from patient 
transport to intensive care unit procedures, must be 
reconceptualized. The process of heart rhythm monitor-
ing is no exception, as placing, changing, and removing 
ECG leads accurately carry a high risk of exposure for the 
frontline health care provider. Minimizing this risk illus-
trates the importance of KardiaMobile 6L and use of an 
accurate, mobile, patient-centric technology in the inpa-
tient setting. By increasing diagnostic accuracy and by 
expanding the automated diagnostic possibilities, there 
is likely to be more widespread acceptance by patients 
and health care providers regarding the utility of mECG 
devices and similar technology.
Limitations
This study was a limited case series of consecutive patients 
willing to participate. A larger sample may reveal issues 
that were not observed in this investigation. Furthermore, 
a larger study would be needed to confirm the accuracy 
of using patient-operated, externally analyzed mECG 
devices to detect significant QTc interval prolongation. In 
addition, due to the limited availability of nonmobile ECGs 
and telemetry, we were unable to concurrently measure 
patients using both mECGs and nonmobile ECGs.
Conclusion
Mobile technology is available for heart rhythm monitor-
ing and has demonstrated diagnostic accuracy and the 
yield of high-quality ECG recordings. In this study, we 
showed that an available product, KardiaMobile 6L, had 
the ability to provide contactless ECGs with acceptable 
QT/QTc interval measurements. Hospitalized patients 
were able to perform recordings with simple instructions 
at the time of first use. Given the heightened importance 
of minimizing infectious disease risk during and beyond 
the COVID-19 pandemic, we strongly believe that 
KardiaMobile 6L can be applied to safely and effectively 
monitor patients at high risk for arrhythmia in both inpa-
tient and outpatient settings.
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